Head to Head Contrast: Greenwich LifeSciences (NASDAQ:GLSI) & Vertex Pharmaceuticals (NASDAQ:VRTX)

Greenwich LifeSciences (NASDAQ:GLSI) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Greenwich LifeSciences and Vertex Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1	0	2	0	2.33
Vertex Pharmaceuticals	0	8	18	2	2.79

Greenwich LifeSciences currently has a consensus price target of $47.50, suggesting a potential upside of 90.92%. Vertex Pharmaceuticals has a consensus price target of $503.80, suggesting a potential upside of 14.15%. Given Greenwich LifeSciences’ higher probable upside, equities analysts clearly believe Greenwich LifeSciences is more favorable than Vertex Pharmaceuticals.

Risk & Volatility

Greenwich LifeSciences has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.

Valuation and Earnings

This table compares Greenwich LifeSciences and Vertex Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$15.79 million	($1.46)	-17.04
Vertex Pharmaceuticals	$11.02 billion	10.16	-$535.60 million	$14.18	31.13

Greenwich LifeSciences has higher earnings, but lower revenue than Vertex Pharmaceuticals. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Greenwich LifeSciences and Vertex Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%
Vertex Pharmaceuticals	31.35%	23.51%	16.80%

Summary

Vertex Pharmaceuticals beats Greenwich LifeSciences on 10 of the 14 factors compared between the two stocks.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.